• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 逃逸的特征:干扰素途径和治疗选择。

Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.

机构信息

Génétique Moléculaire des Virus à ARN Unit, Department of Virology, Institut Pasteur, Université Paris Cité, CNRS UMR3569, 75015 Paris, France.

出版信息

Viruses. 2022 Jun 8;14(6):1247. doi: 10.3390/v14061247.

DOI:10.3390/v14061247
PMID:35746718
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9231409/
Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the current COVID-19 pandemic. SARS-CoV-2 is characterized by an important capacity to circumvent the innate immune response. The early interferon (IFN) response is necessary to establish a robust antiviral state. However, this response is weak and delayed in COVID-19 patients, along with massive pro-inflammatory cytokine production. This dysregulated innate immune response contributes to pathogenicity and in some individuals leads to a critical state. Characterizing the interplay between viral factors and host innate immunity is crucial to better understand how to manage the disease. Moreover, the constant emergence of new SARS-CoV-2 variants challenges the efficacy of existing vaccines. Thus, to control this virus and readjust the antiviral therapy currently used to treat COVID-19, studies should constantly be re-evaluated to further decipher the mechanisms leading to SARS-CoV-2 pathogenesis. Regarding the role of the IFN response in SARS-CoV-2 infection, in this review we summarize the mechanisms by which SARS-CoV-2 evades innate immune recognition. More specifically, we explain how this virus inhibits IFN signaling pathways (IFN-I/IFN-III) and controls interferon-stimulated gene (ISG) expression. We also discuss the development and use of IFNs and potential drugs controlling the innate immune response to SARS-CoV-2, helping to clear the infection.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是当前 COVID-19 大流行的罪魁祸首。SARS-CoV-2 的一个重要特征是能够规避先天免疫反应。早期干扰素(IFN)反应对于建立强大的抗病毒状态是必要的。然而,在 COVID-19 患者中,这种反应较弱且延迟,同时伴有大量促炎细胞因子的产生。这种失调的先天免疫反应导致了发病机制,并在某些个体中导致了危急状态。描述病毒因素与宿主先天免疫之间的相互作用对于更好地了解如何管理该疾病至关重要。此外,新的 SARS-CoV-2 变体不断出现,挑战了现有疫苗的功效。因此,为了控制这种病毒并调整目前用于治疗 COVID-19 的抗病毒疗法,应该不断重新评估研究,以进一步阐明导致 SARS-CoV-2 发病机制的机制。关于 IFN 反应在 SARS-CoV-2 感染中的作用,在这篇综述中,我们总结了 SARS-CoV-2 逃避先天免疫识别的机制。更具体地说,我们解释了这种病毒如何抑制 IFN 信号通路(IFN-I/IFN-III)和控制干扰素刺激基因(ISG)的表达。我们还讨论了 IFNs 的开发和使用以及控制 SARS-CoV-2 先天免疫反应的潜在药物,以帮助清除感染。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7075/9231409/55e320c20f3b/viruses-14-01247-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7075/9231409/55e320c20f3b/viruses-14-01247-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7075/9231409/55e320c20f3b/viruses-14-01247-g001.jpg

相似文献

1
Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.SARS-CoV-2 逃逸的特征:干扰素途径和治疗选择。
Viruses. 2022 Jun 8;14(6):1247. doi: 10.3390/v14061247.
2
Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.I型、II型和III型干扰素的抗病毒活性可抵消ACE2的诱导性并限制新型冠状病毒。
mBio. 2020 Sep 10;11(5):e01928-20. doi: 10.1128/mBio.01928-20.
3
SARS-CoV-2 Evasion of the Interferon System: Can We Restore Its Effectiveness?SARS-CoV-2 逃避干扰素系统:我们能否恢复其有效性?
Int J Mol Sci. 2023 May 27;24(11):9353. doi: 10.3390/ijms24119353.
4
An Update on Innate Immune Responses during SARS-CoV-2 Infection.关于 SARS-CoV-2 感染期间固有免疫反应的最新研究进展。
Viruses. 2021 Oct 14;13(10):2060. doi: 10.3390/v13102060.
5
Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19.对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的固有免疫和炎症反应:对冠状病毒病(COVID-19)的影响
Cell Host Microbe. 2021 Jul 14;29(7):1052-1062. doi: 10.1016/j.chom.2021.05.004. Epub 2021 May 17.
6
Mechanisms of Antiviral Immune Evasion of SARS-CoV-2.SARS-CoV-2 抗病毒免疫逃逸的机制。
J Mol Biol. 2022 Mar 30;434(6):167265. doi: 10.1016/j.jmb.2021.167265. Epub 2021 Sep 22.
7
Type I and Type III Interferons Restrict SARS-CoV-2 Infection of Human Airway Epithelial Cultures.Ⅰ型和Ⅲ型干扰素限制 SARS-CoV-2 感染人呼吸道上皮细胞。
J Virol. 2020 Sep 15;94(19). doi: 10.1128/JVI.00985-20.
8
SARS-CoV-2-mediated evasion strategies for antiviral interferon pathways.SARS-CoV-2 介导的抗病毒干扰素途径的逃逸策略。
J Microbiol. 2022 Mar;60(3):290-299. doi: 10.1007/s12275-022-1525-1. Epub 2022 Feb 5.
9
Interplay between SARS-CoV-2 and the type I interferon response.SARS-CoV-2 与 I 型干扰素应答的相互作用。
PLoS Pathog. 2020 Jul 29;16(7):e1008737. doi: 10.1371/journal.ppat.1008737. eCollection 2020 Jul.
10
Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19.冠状病毒感染与干扰素反应:病毒-宿主的军备竞赛与 COVID-19。
Viruses. 2022 Jun 21;14(7):1349. doi: 10.3390/v14071349.

引用本文的文献

1
Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial.间歇性禁食和无糖饮食对新冠长期症状的影响:一项随机交叉试验。
Sci Rep. 2025 Jul 29;15(1):27563. doi: 10.1038/s41598-025-07461-0.
2
Innate immunity, therapeutic targets and monoclonal antibodies in SARS-CoV-2 infection.新型冠状病毒感染中的固有免疫、治疗靶点及单克隆抗体
PeerJ. 2025 Jun 20;13:e19462. doi: 10.7717/peerj.19462. eCollection 2025.
3
Antimicrobial Potential of Cannabinoids: A Scoping Review of the Past 5 Years.大麻素的抗菌潜力:过去5年的范围综述

本文引用的文献

1
Serum IL-28A/IFN-λ2 is linked to disease severity of COVID-19.血清 IL-28A/IFN-λ2 与 COVID-19 疾病严重程度相关。
Sci Rep. 2022 Mar 31;12(1):5458. doi: 10.1038/s41598-022-09544-8.
2
Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2.靶向 Nsp1-核糖体复合物的药物显示出抗 SARS-CoV-2 的抗病毒活性。
Elife. 2022 Mar 24;11:e74877. doi: 10.7554/eLife.74877.
3
The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2.
Microorganisms. 2025 Feb 2;13(2):325. doi: 10.3390/microorganisms13020325.
4
A systems biology approach unveils different gene expression control mechanisms governing the immune response genetic program in peripheral blood mononuclear cells exposed to SARS-CoV-2.一种系统生物学方法揭示了在暴露于SARS-CoV-2的外周血单核细胞中,控制免疫反应遗传程序的不同基因表达调控机制。
PLoS One. 2024 Dec 5;19(12):e0314754. doi: 10.1371/journal.pone.0314754. eCollection 2024.
5
Viral interference between severe acute respiratory syndrome coronavirus 2 and influenza A viruses.严重急性呼吸综合征冠状病毒2与甲型流感病毒之间的病毒干扰
PLoS Pathog. 2024 Jul 22;20(7):e1012017. doi: 10.1371/journal.ppat.1012017. eCollection 2024 Jul.
6
Immunological mechanisms of the nucleocapsid protein in COVID-19.新型冠状病毒核衣壳蛋白的免疫学机制。
Sci Rep. 2024 Feb 14;14(1):3711. doi: 10.1038/s41598-024-53906-3.
7
COVID-19 induces more pronounced extracellular matrix deposition than other causes of ARDS.COVID-19 比其他 ARDS 病因引起更明显的细胞外基质沉积。
Respir Res. 2023 Nov 14;24(1):281. doi: 10.1186/s12931-023-02555-7.
8
Interferons-Implications in the Immune Response to Respiratory Viruses.干扰素——对呼吸道病毒免疫反应的影响
Microorganisms. 2023 Aug 29;11(9):2179. doi: 10.3390/microorganisms11092179.
9
Host mitochondria: more than an organelle in SARS-CoV-2 infection.宿主线粒体:不止是 SARS-CoV-2 感染中的一个细胞器。
Front Cell Infect Microbiol. 2023 Aug 25;13:1228275. doi: 10.3389/fcimb.2023.1228275. eCollection 2023.
10
Influence of polymorphic variations of IFNL, HLA, and IL-6 genes in severe cases of COVID-19.IFNL、HLA 和 IL-6 基因多态性变化对 COVID-19 重症病例的影响。
Exp Biol Med (Maywood). 2023 May;248(9):787-797. doi: 10.1177/15353702231181343. Epub 2023 Jul 15.
冠状病毒通过突变和重组实现的惊人进化可塑性:对 COVID-19 大流行及 SARS-CoV-2 未来进化路径的启示。
Viruses. 2022 Jan 2;14(1):78. doi: 10.3390/v14010078.
4
NSP9 of SARS-CoV-2 attenuates nuclear transport by hampering nucleoporin 62 dynamics and functions in host cells.SARS-CoV-2 的 NSP9 通过干扰宿主细胞核孔蛋白 62 的动力学和功能来减弱核转运。
Biochem Biophys Res Commun. 2022 Jan 1;586:137-142. doi: 10.1016/j.bbrc.2021.11.046. Epub 2021 Nov 20.
5
Structures and functions of coronavirus replication-transcription complexes and their relevance for SARS-CoV-2 drug design.冠状病毒复制-转录复合物的结构和功能及其与 SARS-CoV-2 药物设计的相关性。
Nat Rev Mol Cell Biol. 2022 Jan;23(1):21-39. doi: 10.1038/s41580-021-00432-z. Epub 2021 Nov 25.
6
Interferon-Lambda Intranasal Protection and Differential Sex Pathology in a Murine Model of SARS-CoV-2 Infection.干扰素-λ 经鼻保护和 SARS-CoV-2 感染的小鼠模型中的性别差异病理学。
mBio. 2021 Dec 21;12(6):e0275621. doi: 10.1128/mBio.02756-21. Epub 2021 Nov 2.
7
X-Linked TLR7 Deficiency Underlies Critical COVID-19 Pneumonia in a Male Patient with Ataxia-Telangiectasia.X 连锁 TLR7 缺陷导致共济失调毛细血管扩张症男性患者发生重症 COVID-19 肺炎。
J Clin Immunol. 2022 Jan;42(1):1-9. doi: 10.1007/s10875-021-01151-y. Epub 2021 Oct 23.
8
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.干扰素 β-1a 联合瑞德西韦与单用瑞德西韦治疗住院 COVID-19 成人患者的疗效比较:一项双盲、随机、安慰剂对照、3 期临床试验。
Lancet Respir Med. 2021 Dec;9(12):1365-1376. doi: 10.1016/S2213-2600(21)00384-2. Epub 2021 Oct 18.
9
The N-terminal domain of SARS-CoV-2 nsp1 plays key roles in suppression of cellular gene expression and preservation of viral gene expression.新型冠状病毒 2 号 nsp1 的 N 端结构域在抑制细胞基因表达和维持病毒基因表达方面发挥关键作用。
Cell Rep. 2021 Oct 19;37(3):109841. doi: 10.1016/j.celrep.2021.109841. Epub 2021 Sep 30.
10
SARS-CoV-2 Nsp5 Demonstrates Two Distinct Mechanisms Targeting RIG-I and MAVS To Evade the Innate Immune Response.SARS-CoV-2 Nsp5 采用两种不同机制靶向 RIG-I 和 MAVS 以逃避先天免疫反应。
mBio. 2021 Oct 26;12(5):e0233521. doi: 10.1128/mBio.02335-21. Epub 2021 Sep 21.